TIDMGSK
RNS Number : 5175D
GlaxoSmithKline PLC
19 February 2020
GlaxoSmithKline plc (the ' Company ')
2020 Performance Share Plan Award and 2020 Performance
Measures
2020 Performance Share Plan Award
On 14 February 2020, the Company granted conditional share
awards to the Executive Directors, other Persons Discharging
Managerial Responsibilities ('PDMRs') and their Persons Closely
Associated ('PCA') under the GlaxoSmithKline 2017 Performance Share
Plan ('the Plan'). The Plan was approved by shareholders on 4 May
2017 and allows a performance-related opportunity in the form of
conditional awards to be granted to senior executives in the Group,
including the Executive Directors and other PDMRs.
Under the terms of the Plan, conditional awards are granted over
a specific number of Ordinary Shares or American Depositary Shares
('ADSs'), and the percentage of awards that ultimately vests is
dependent on the level of achievement against performance targets
set by the Remuneration Committee.
2020 Performance Measures
In accordance with the current Remuneration Policy and following
engagement with shareholders, the Remuneration Committee has
determined that, beginning in 2020, a new performance measure,
Pipeline Progress, is being introduced. This new measure is
targeted to support GSK's Innovation business priority and reward
progress in strengthening our R&D pipeline with high quality
assets and in achieving approvals in major markets for key assets
or indications. The focus of the metric will be on the achievement
of material milestones. This has particular importance as the
Company works towards separation.
The performance period for the awards is the three financial
years from 1 January 2020 to 31 December 2022. The awards will be
based on four measures:
Performance Measure Proportion of
each award
Relative Total Shareholder Return (TSR) 30%
--------------
Adjusted Free Cash Flow (AFCF) 30%
--------------
Innovation Sales (name changed from R&D New
Products) 20%
--------------
Pipeline Progress 20%
--------------
Relative TSR measure
This measure compares the TSR of the Company's Ordinary Shares
over the performance period with the TSR of the shares of nine (9)
other global pharmaceutical companies (i.e. a comparator group of
ten (10) companies including the Company). This TSR comparator
group remains unchanged. The companies in the TSR comparator group
are AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson &
Johnson, Merck & Co, Novartis, Pfizer, Roche Holdings, Sanofi
and GlaxoSmithKline.
In a group of 10 companies, the median (position 5.5) falls
between two companies. The vesting schedule for the 2020 awards is
as follows:
Ranking position Vesting Schedule
1st, 2nd or 3rd 100%
-----------------
4th 70%
-----------------
5th 40%
-----------------
Median (Threshold vesting) 25%
-----------------
6th or below 0%
-----------------
Adjusted Free Cash Flow (AFCF) measure
The use of cash flow as a performance measure is intended to
recognise the importance of effective working capital management
and of generating cash to fund the Group's operations, investments,
and ordinary dividends to shareholders.
Free cash flow represents the operating profit of the business
adjusted for non-cash items after deducting the cost or benefit of
working capital, capital expenditure, contingent consideration
payments, net interest, dividends paid to non-controlling interests
and taxation.
The adjustments to free cash flow, used to set the AFCF target
for the purpose of this performance measure, include foreign
exchange, legal, special pension contributions, and the impact of
divestments and acquisitions. The measure post-adjustment is the
"adjusted free cash flow" target.
This element of the 2020 award will vest as follows:
Performance Level Adjusted Free Cash Proportion Vesting
Flow target
Below threshold < GBP9.99bn 0%
-------------------- -------------------
Threshold GBP9.99bn 25%
-------------------- -------------------
GBP10.30bn 50%
---------------------------------------- -------------------
GBP11.33bn 75%
---------------------------------------- -------------------
Maximum GBP11.84bn 100%
-------------------- -------------------
The proportions vesting between the above vesting levels will be
calculated on a straight-line basis.
Innovation Sales measure
Due to commercial sensitivity, the Remuneration Committee
remains of the view that the Innovation Sales measure product
target cannot be published at the time of grant. However, the
target and vesting outcome will be disclosed in full at the end of
the performance period.
25% of this element will vest if the performance threshold level
is attained, rising to 100% for stretching performance exceeding
122% of the set threshold. Below the set threshold, none of this
element will vest.
Pipeline Progress measure
The new Pipeline Progress measure is being introduced to
increase our emphasis on Innovation and to reward acceleration and
strengthening of the pipeline. The measure is based on two equally
weighted elements of our key assets or indications:
Proportion
of LTI Pipeline Progress - Sub-measure
award
10% Pivotal trial starts , which will focus mainly on phase
III registrational trial starts, but may also include
phase II starts (for example, in oncology)
--------------------------------------------------------
10% Major regulatory approval milestones
--------------------------------------------------------
Points will be allocated to the successful assets in each
sub-measure based upon their forecast commercial value (peak year
sales) at the end of the performance period.
These sub-measures of the 2020 award will vest as follows:
Pivotal Trial Starts
Performance Level Points Payout
Below Threshold <13 Nil
------- -------
Threshold 13 25%
------- -------
14 50%
------- -------
15 75%
------- -------
Maximum 18 100%
------- -------
Major Regulatory Approvals
Performance Level Points Payout
Below Threshold <18 Nil
------- -------
Threshold 18 25%
------- -------
19 50%
------- -------
20 75%
------- -------
Maximum 22 100%
------- -------
Where relevant, achievements between the above performance
levels will be rewarded on a straight-line basis. At the end of the
performance period we will provide full disclosure of what has been
achieved, in terms of both milestones and aggregate points, along
with a narrative commentary on performance.
Notes
1. To the extent that each element of a conditional award does
not vest at the end of the three-year performance period, it will
lapse.
2. The Executive Directors and other PDMRs in the transaction
notifications below were each granted a conditional award under the
terms of the GlaxoSmithKline 2017 Performance Share Plan. Awards
granted are of Ordinary Shares or ADSs.
3. Dividends will accrue on the conditional award of Ordinary
Shares or ADSs during the performance period, but will only vest to
the extent that the awards themselves vest at the end of the
performance period. These dividends are not included in the figures
below.
4. For Executive Directors, the award is subject to an
additional vesting period of two years (the 'Holding Period') from
the normal vesting date, i.e. five years in total. During the
additional Holding Period, the relevant Ordinary Shares or ADSs
would only be forfeited in the event that the Executive Director
was terminated for cause, and the Ordinary Shares or ADSs will
continue to carry rights to dividend equivalents.
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Ms E Walmsley
==== ===================================== ===================================================
b) Position/status Chief Executive Officer
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 392,260
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Dr H Barron
==== ======================================== ====================================================
b) Position/status Chief Scientific Officer and President,
R&D
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ======================================== ====================================================
b) Nature of the A conditional award of ADSs under the Company's
transaction 2017 Performance Share Plan.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$43.78 203,981
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2020-02-14
==== ======================================== ====================================================
f) Place of the N/A
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr R Connor
==== ===================================== ===================================================
b) Position/status President, Global Vaccines
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 162,474
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Ms D Conrad
==== ===================================== ===================================================
b) Position/status SVP, Human Resources
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 80,468
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr J Ford
==== ======================================= =================================================
b) Position/status SVP & General Counsel
==== ======================================= =================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= =================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ======================================= =================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ======================================= =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ======================== ====================
GBP16.814 129,237
===================================================================== ====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ======================================= =================================================
f) Place of the N/A
transaction
==== ======================================= =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr N Hirons
==== ===================================== ===================================================
b) Position/status SVP, Global Ethics and Compliance
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 51,980
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Ms S Jackson
==== ===================================== ===================================================
b) Position/status SVP, Global Communications & CEO Office
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 49,012
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr D Jackson
==== ===================================== =======================================================
b) Position/status PCA of Ms S Jackson (SVP, Global Communications
& CEO Office)
==== ===================================== =======================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== =======================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== =======================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== =======================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== =======================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== =======================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ====================== =====================
GBP16.814 5,570
.
======================================================================= =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
==================================================================== =============================
e) Date of the transaction 2020-02-14
==== ===================================== =======================================================
f) Place of the N/A
transaction
==== ===================================== =======================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr I Mackay
==== ======================================= =================================================
b) Position/status Chief Financial Officer
==== ======================================= =================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= =================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ======================================= =================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ======================================= =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ======================== ====================
GBP16.814 207,267
===================================================================== ====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ======================================= =================================================
f) Place of the N/A
transaction
==== ======================================= =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr B McNamara
==== ======================================== ====================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ======================================== ====================================================
b) Nature of the A conditional award of ADSs under the Company's
transaction 2017 Performance Share Plan.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$43.78 94,545
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2020-02-14
==== ======================================== ====================================================
f) Place of the N/A
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr L Miels
==== ===================================== ===================================================
b) Position/status President, Global Pharmaceuticals
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 181,957
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr D Redfern
==== ===================================== ===================================================
b) Position/status Chief Strategy Officer
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 149,965
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr R Simard
==== ===================================== ===================================================
b) Position/status President, Pharmaceuticals Supply Chain
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 94,207
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Ms K Terrell
==== ======================================== ====================================================
b) Position/status Chief Digital & Technology Officer
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ======================================== ====================================================
b) Nature of the A conditional award of ADSs under the Company's
transaction 2017 Performance Share Plan.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$43.78 78,712
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2020-02-14
==== ======================================== ====================================================
f) Place of the N/A
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr P Thomson
==== ===================================== ===================================================
b) Position/status President, Global Affairs
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 68,490
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Ms D Waterhouse
==== ===================================== ===================================================
b) Position/status CEO of ViiV Healthcare
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 80,290
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Ms V Whyte
==== ===================================== ===================================================
b) Position/status Company Secretary
==== ===================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== ===================================================
b) Nature of the A conditional award of Ordinary Shares
transaction under the Company's 2017 Performance Share
Plan.
==== ===================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ===================== ===================
GBP16.814 11,800
.
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===========================
e) Date of the transaction 2020-02-14
==== ===================================== ===================================================
f) Place of the N/A
transaction
==== ===================================== ===================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHQKLFFBLLLBBQ
(END) Dow Jones Newswires
February 19, 2020 11:28 ET (16:28 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024
